Cargando…

Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia

SIMPLE SUMMARY: Chronic myeloid leukaemia (CML) is a type of blood cancer that is currently well-managed with drugs that target cancer-causing proteins. However, a significant proportion of CML patients do not respond to those drug treatments or relapse when they stop those drugs because the cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poudel, Govinda, Tolland, Molly G., Hughes, Timothy P., Pagani, Ilaria S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317051/ https://www.ncbi.nlm.nih.gov/pubmed/35884363 http://dx.doi.org/10.3390/cancers14143300

Ejemplares similares

A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota-Immune Crosstalk in Disease Progression and Relapse
por: Pagani, Ilaria S., et al.
Publicado: (2022)

Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
por: Carrà, Giovanna, et al.
Publicado: (2019)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia
por: Yang, Jingmei, et al.
Publicado: (2023)

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
por: Russo, D, et al.
Publicado: (2015)

Chronic myeloid leukaemia with marked thrombocytosis
por: Ooi, Jun, et al.
Publicado: (2020)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

Desacetylmethylcolchicine in the Treatment of Myeloid Leukaemia
por: Jelliffe, A. M., et al.
Publicado: (1956)

Molecular Mechanisms and Therapies of Myeloid Leukaemia
por: Brown, Elliott, et al.
Publicado: (2022)

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
por: Korfi, K., et al.
Publicado: (2015)

Prospects for achieving treatment‐free remission in chronic myeloid leukaemia
por: Saglio, Giuseppe, et al.
Publicado: (2020)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020)

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia
por: Ochi, Yotaro, et al.
Publicado: (2021)

Chronic Myeloid Leukaemia in The 21st Century
por: Frazer, Rachel, et al.
Publicado: (2007)

COVID-19 in persons with chronic myeloid leukaemia
por: Li, Weiming, et al.
Publicado: (2020)

Isolated Ocular Manifestations in Chronic Myeloid Leukaemia
por: Maniam, Anita, et al.
Publicado: (2021)

Two ophthalmic presentations of chronic myeloid leukaemia
por: Kiernan, Miles, et al.
Publicado: (2022)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro
por: Husaini, Roslina, et al.
Publicado: (2017)

Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients
por: Schmitz, Ulf, et al.
Publicado: (2020)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

Why are patients with chronic myeloid leukaemia (non-)adherent?
por: Abraham, I, et al.
Publicado: (2012)

The underestimated role of basophils in Ph(+) chronic myeloid leukaemia
por: Valent, Peter, et al.
Publicado: (2018)

Acute abdomen in a patient with chronic myeloid leukaemia
por: Voppuru, Saiesh Reddy, et al.
Publicado: (2020)

Survival with chronic myeloid leukaemia after failing milestones
por: Lauseker, Michael, et al.
Publicado: (2023)

Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia
por: Yan, W-H, et al.
Publicado: (2008)

Induction of Resistance Against Isotransplantation of Virus-Induced Myeloid Leukaemias
por: Pasternak, G., et al.
Publicado: (1963)

Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
por: Chen, Teng-Chou, et al.
Publicado: (2013)

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
por: Copland, Mhairi
Publicado: (2022)

Myeloid Leukæmia: The Treatment by Deep X-Rays
por: Napier, L. Everard, et al.
Publicado: (1937)

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia
por: Lebecque, Benjamin, et al.
Publicado: (2022)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
por: Hughes, Timothy P., et al.
Publicado: (2017)

In vitro generation of lymphocytotoxicity to autochthonous leukaemic cells in chronic myeloid leukaemia.
por: Khare, A. G., et al.
Publicado: (1981)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.
por: Gangal, S. G., et al.
Publicado: (1979)

A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells
por: Smith, Paul G., et al.
Publicado: (2012)

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors
por: Thijsen, S F T, et al.
Publicado: (1999)

S150: TIMING AND CLONAL TRAJECTORY TO CHRONIC MYELOID LEUKAEMIA DRIVEN BY THE PHILADELPHIA CHROMOSOME
por: Kamizela, Aleksandra, et al.
Publicado: (2023)

Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia
por: Samaiya, Misti, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_svg0tievobv75dbscudm8vep9j